A phase I trial shows the mKRAS-VAX vaccine can stimulate long-term T-cell responses in individuals with precancerous pancreatic lesions and is well tolerated.

A Phase 1b trial of the immunotherapy IBC-Ab002 has successfully met safety endpoints, marking a potential shift in treating Alzheimer's as a systemic immune disorder.

A study published in Gut Microbes details how the bacterium Ewingella americana, isolated from Japanese tree frogs, achieved 100% tumor clearance in mice.

Immunotherapy is shifting the survival landscape for patients with advanced cancers by training the immune system to target malignant cells. While these treatments have led to significant clinical breakthroughs, experts emphasize that sustainable research funding remains vital.